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There are few studies on the pharmacological properties of Valeriana prionophylla Standl. (VP), known as “Valeriana del monte”,
and used in Mesoamerican folk medicine to treat sleep disorders. This study examines the pharmacological eﬀects of the
hydroalcoholic extract of the dry rhizome using the open ﬁeld, rota rod, elevated plus-maze (EPM), forced swimming (FST),
strychnine- and pentobarbital-induced sleeping time, PTZ-induced seizures, and the inhibitory avoidance tests. VP did not show
any protective eﬀect against PTZ-induced convulsions. In the EPM, exhibited an anxiolytic-like eﬀect through the eﬀective
enhancement of the entries (38.5%) and time spent (44.7%) in the open arms, when compared with control group. Time
spent and the numbers of entrances into the enclosed arms were decreased, similar to those eﬀects observed with diazepam.
In the FST, acute treatment with VP, produced a dose-dependent decrease in immobility time, similarly to imipramine. VP also
produced a signiﬁcant dose-dependent decrease in the latency of sleeping time, while producing an increase in total duration
of sleep; inﬂuenced memory consolidation of the animals only at lower doses, unlike those that produced anti-depressant and
anxiolytic eﬀects. In summary, the results suggest that VP presents several psychopharmacological activities, including anxiolytic,
antidepressant, and hypno-sedative eﬀects.
1.Introduction
Worldwide epidemiological studies since the 1970s indicate
that about 30% of the adult population suﬀer from some
form of sleep disorder [1, 2], and 15% to 25% are aﬀected by
episodes of anxiety, suggesting that this is a silent epidemic
of the 21st century [3].
The use of medicinal plants for the symptomatic treat-
ment of anxiety, insomnia, and various nervous disorders is
well known and has increased signiﬁcantly in recent years
[4, 5]. The main plant drug used for these pathologies is
Valeriana oﬃcinalis L., a European plant that is accepted by
most international pharmacopoeias [6, 7], but is exotic to
Mesoamerica, were it needs to be imported for clinical use.
After ethnobotanical surveys, commercial availability in
popular markets, and community-based primary healthcare
groups, several species of so-called “valeriana” were identi-
ﬁed,somebelongingtothegenusValeriana [8,9],andothers
tothe Asteraceaeor Poaceaefamily,some of them containing
valepotriates [10]. After carrying out a nationwide survey,
ten samples of Valeriana prionophylla Standl. (VP) were
collected, selecting the plant that grows in Concepci´ on
Tututapa, as a possible equivalent to V. oﬃcinalis.
V. prionophylla is a perennial plant, which grows up to
10–80cm in height, with small yellow or pale purple ﬂowers
inalongpeduncle;therootsare12–20cmlong,4-5cmwide,
and it has a strong characteristic odor. It has been described
growing in regions from Mexico to Costa Rica, at altitudes
above 1500m [11]. Of the scant studies on this plant species
intheinternationalliterature,onedemonstratesthepresence
of monterpenic iridoids (valerate, isovalerate, homovalerate,
and didrovaltrate) [12], and another, its antioxidant and2 Evidence-Based Complementary and Alternative Medicine
vasorelaxant activity, which is attributed to the presence of
iridoids (7,9 :7 ,9-diepoxylignan glycosides) [13]. National
publications demonstrate that oral administration in mice
does not show any signs of toxicity after administration for
eight days (DL50 > 1,200mg/kg) [14]; in 28 elderly patients
with insomnia, a 1:5 tincture showed control of insomnia,
and no secondary eﬀects were observed [15]. Since this plant
species is included in the oﬃcial list of medicinal plants
from Guatemala [16] and phytochemically seems to be very
similartothespeciesValeriana oﬃcinalis,theaimherewasto
demonstrate the behavioural and pharmacological activities
observed in animals treated with ethanol extract of this
specie.
2.MaterialsandMethods
2.1. Plant Material. Material was collected from cultiva-
tion in Tierra Blanca, Concepci´ on Tutuapa, San Marcos
(15◦14.808 N, 91◦55.430 W), Guatemala, a vegetation zone
thatbelongstoaveryhumidlowmontaneforest.Three-year-
old rhizomes and roots were dug up, washed, and shade-
dried. Botanical samples were determined by Mario Veliz at
Herbarium BIGU, School of Biology, USAC, and a voucher
sample deposited (no. 49183).
2.2.PreparationofEthanolExtract. Drymaterialwasground,
wet with 50% ethanol, and placed in a stainless steel percola-
tor. 50% ethanol was added to obtain a tincture, which was
concentrated in a rotavapor. Fresh ethanol was added for ﬁve
consecutive days and the extract was concentrated. The ﬁnal
drying was performed in a vacuum dryer with silica gel [17].
The average yield of the extractable solids was 28.52%.
2.3. Drugs. Distilled water with 1drop/ml of DMSO was
used as vehicle. Diazepam (Crist´ alia, Brazil) was used as
the reference drug (positive control) for anxiolytic, sedative,
muscle relaxant, and anticonvulsant activities. Pentylenete-
trazol and strychnine (Sigma, USA; 4.0mg/kg) were used
to induce convulsions. Sodium pentobarbital (Sigma, USA;
50mg/kg) was used to induce sleep; lorazepam (Crist´ alia,
Brazil) was used as positive control for hypnotic activity.
Imipramine (Sigma, USA) was used as the standard drug for
antidepressant eﬀect, and phenobarbital (Sigma, USA) as the
reference drug for anticonvulsant activity.
2.4. Animals. Nonfasted adult female Swiss mice (18–35g)
and male Wistar rats (150–220g) were used in the experi-
ments. The animals were kept in a controlled-temperature
environment (22 ± 3◦C), illuminated by daylight and
supplemented with electric light from 7:00 a.m. to 7:00
p.m., with free access to food and water. The experiments
were performed after approval of the protocol by the
Institutional Ethics Committee of UNIVALI 3008/2007, and
were carried out in accordance with the current guidelines
for the care of laboratory animals, and the ethical guidelines
for investigations in Brazil, COBEA (Brazilian College of
Animal Experimentation) [18]. The number of animals and
intensity of the noxious stimuli used were the minimum
necessary to demonstrate the consistent eﬀects of the drug
treatments.
2.5. Measurement of Motor Performance: Rota Rod Test. To
evaluate possible nonspeciﬁc muscle relaxant eﬀects of VP
extract, the mice were tested on the rota-rod [19]. The
apparatus consists of a bar with a diameter of 2.5cm,
subdivided into six compartments by disks of 25cm in
diameter (Ugo Basile, Model 7600). The bar was rotated at
a constant speed of 22rpm. The animals were selected 24h
previously in order to eliminate those that did not remain
on the bar for two consecutive periods of 60sec. The animals
were treated with VP extract (50–150mg/kg, p.o.) or with
the same volume of vehicle NaCl 0.9% solution with 2% of
Tween 80, 60min before the test. The results are expressed as
the time in sec. that the animals remained on the rota-rod.
The cut-oﬀ time used was 60sec.
2.6. Open-Field Test (OF). The open-ﬁeld arena was made
of acrylic (transparent walls and black ﬂoor). The arena
measured 30×30×15cm, divided into nine squares of equal
areas. The open-ﬁeld was used to evaluate the exploratory
activity of the animals [20]. The animals received VP extract
(50–150mg/kg, p.o.) and vehicle 60min prior to the tests.
They were placed individually in the center of the arena,
and allowed to explore freely. The observed parameters were:
ambulation or crossing (the number of squares crossed with
all four paws) and numbers of rearings, both indicators
being recorded for the last 5min of the 6min testing
period.
2.7. Pentobarbital-Induced Hypnosis. In order to evalu-
ate hypnosis potentiating activity, sodium pentobarbital
(50mg/kg, i.p.) was injected into female mice after oral
administration of VP extract (50, 100, and 150mg/kg). The
latency and hypnosis time were recorded. Hypnosis time was
measured by the loss of the righting reﬂex, recovery of this
reﬂex being considered as the end of the hypnosis time [21].
Lorazepam (2.0mg/kg, i.p.) administered 30min before the
test was used as a reference drug.
2.8. Elevated Plus-Maze Test (EPM). The procedure used to
evaluate the possible anxiolytic eﬀect was similar to that
described previously [22, 23]. The wooden EPM apparatus
was shaped in the form of a cross, with two open arms
(50 × 10cm2) with sides of 1cm in height, and two closed
arms(50×10×15cm).Thecentralareaofthemazemeasured
10×10cm2. The apparatus was elevated to a height of 70cm.
During the test, each animal was placed at the center of the
maze facing the closed arm 60min after administration of
VP extract (50–150mg/kg, p.o.) or vehicle. All entries to the
open or closed arms were scored for 5min, and the total
t i m es p e n ti ne a c ha r mw a sr e c o r d e d .A ne n t r yw a sd e ﬁ n e d
as placing the mouse’s four paws into an arm, and no time
was recorded when the animal was in the center of the maze.
Diazepam (0.75mg/kg, i.p., administered 30min before the
test) was used as a reference drug.Evidence-Based Complementary and Alternative Medicine 3
2.9.ForcedSwimmingTest(FST). TheFSTisthemostwidely
used pharmacological model for assessing antidepressant
activity [24]. This method is based on the observation that
animals exposed to a situation of forced swimming became
passive and immobile after a period of vigorous activity
(struggling) and produced only enough movements to keep
their heads above the water. The FST was carried out on
miceaccordingtoPorsoltetal.[25].Swimmingsessionswere
conducted by placing the animals in an individual Plexiglass
cylinder (46cm high × 20cm diameter) containing 20cm of
water at 24 ± 1◦C. All the animals were forced to swim for
6min. The amount of time spent in struggling (ﬁrst 2min of
experiment) and immobile during the ﬁnal 4-min interval of
the test was manually recorded by competent observers. VP
extract (50–150mg/kg, p.o.), imipramine (10mg/kg, i.p.) or
vehicle was administered, 60 and 30min before the test.
2.10. Pentylenetetrazole- (PTZ-) and Strychnine- (STR-) In-
duced Convulsions. Seizures were chemically induced with
PTZ and STR, as described by Ali et al. [26] and Yamashita
et al. [27] with minor modiﬁcations. Groups of 8–10mice
were treated with the VP extract (50–150mg/kg, p.o.),
phenobarbital (40mg/kg, i.p.), or vehicle, and 30 and
60min afterwards, they received a convulsant dose of PTZ
(100mg/kg, i.p.) or STR (4.0mg/kg, i.p.). Immediately after
treatment with the convulsant agents, the animals were
placed individually in cages and observed for 60min. The
time of the onset of seizures, and mortality, were assessed
during this time.
2.11. Inhibitory Avoidance (IA). R a t sw e r et r a i n e di nao n e -
trial,step-downIAparadigm,ahighlyvalidatedlearningtask
in which stepping down from a platform present in a given
contextisassociatedwithafootshockresultinginanincrease
in step-down latency [28, 29]. The IA apparatus consisted of
a5 0×25×25cmPlexiglass box witha5×8×25cm platform
on the left end of a series of bronze bars that constitutes the
ﬂoor of the box. During training, the animals were gently
placed on the platform facing the left rear corner of the
training box. When they stepped down and placed their four
pawsonthegrid,theyreceiveda2-second,0.4mAscrambled
foot shock. Afterwards, they were immediately withdrawn
from the training box. Memory retention was evaluated in
a test session carried out 24h after the training. In the test,
the trained animals were placed back on the training box
platform until they eventually stepped down onto the grid.
The latency to step-down during the test session was taken
as an indicator of memory retention. A ceiling of 180sec was
imposedforstep-downlatenciesduringtheretentiontest.To
evaluate the eﬀect on memory consolidation, the treatment
with VP extract (50–150mg/kg, p.o.), or vehicle were given
60min after training.
2.12.StatisticalAnalysis. Theresultsarepresentedasmean ±
SEM. For the parametric data, the variables were analyzed by
one-wayanalysisofvariance(ANOVA),followedbyStudent-
Newman-Keuls analysis. P values <.05 were considered as
indicative of signiﬁcance. For the statistical analysis of
non-parametric data from the IA test, the Mann-Whitney
U-test was used.
3. Results
3.1.Rota-RodTest. Neitherofthedosesofextractused,given
p.o. 60min beforehand, signiﬁcantly aﬀected the motor
response of the animals when assessed in the rota-rod test.
This eﬀect was only observed in the animals treated with
diazepam (data not shown).
3.2. OF. VP extract, at doses of 100 and 150mg/kg, showed
sedative eﬀects in mice, as assessed by the OF (Figure 1).
Signiﬁcant eﬀects were detected with both doses, which pro-
duced inhibition (28.57 and 39.80%, resp.) in the number of
crossings(P<. 05)comparedwiththecontrols(Figure 1(a)).
T h en u m b e ro fr e a r i n g s( Figure 1(b)) was also signiﬁcantly
decreased with both doses, which produced percentages of
inhibition of 48.75 and 56.25%, (P<. 5, P<. 01, resp.).
Haloperidol, used as positive control, produced a statistically
signiﬁcant decrease in both parameters.
3.3. Pentobarbital-Induced Hypnosis. In the barbiturate-
induced sleeping time test, i.p. administration of VP extract
10, 50, and 100mg/kg, respectively, decreased (F = 15.26)
the latency sleep time by 71.62, 76.0 and 85.8%, respectively
(Figure 2(a)). Treatment with VP extract (q = 6.362 P<
.01, q = 6.141 P<. 01, q = 5.778 P<. 01) produced
a statistical and dose-dependent increase in total sleep time
(62.8,60.6,and57.0%,resp.)suggestingapotentiationofthe
pentobarbital eﬀect (Figure 2(b)).
3.4. EPM. A possible anxiolytic activity of VP was assessed
by the EPM. The results (Figures 3(a) and 3(b)) showed that
the extract (150mg/kg, p.o.) promoted a modiﬁcation in the
number of entrances to the open arms (q = 3.326, P<. 01)
and the time spent in the open arms (q = 2.545, P<
.05), which were signiﬁcantly increased by 38.5 and 44.7%,
respectively, compared with the controls. On the other hand,
the same dose of VP extract (150mg/kg, i.p.) promoted a
decrease in the time spent and the number of entrances to
the closed arms (Figures 3(c) and 3(d)),(q = 4.217, P<. 01)
of 32.5 and 25.60%. In this experiment, the anxiolytic eﬀect
of diazepam was also observed.
3.5. FST. As shown in Figure 4(a), it was observed that acute
treatment with the extract exhibited a signiﬁcant increase in
the time spent struggling (F = 111.71, P< . 01). This eﬀect
was observed in all the doses used (50, 100 and 150mg/kg,
p.o.). It was also observed that treatment with the extract
promoted a signiﬁcant increase in immobility time (F =
64.402, P< . 01) in 35.60, 64.60, and 73.70%, compared
with the controls (Figure 4(b)). The antidepressant eﬀect of
imipramine was observed in both parameters.
3.6. PTZ and STR-Induced Convulsions. Comparison be-
tween the treatment of animals with VP extract (50–
150mg/kg), phenobarbital (40mg/kg) and the control group4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of acute administration of hydroalcoholic extract
of Valeriana prionophylla (50, 100 and 150mg/kg, p.o.) and
haloperidol (2,5mg/kg, i.p.), in the open ﬁeld test in mice. (a)
Number of crossings and (b) number of rearings. Each bar
represents the mean ± S E M ,f r o m6t o1 0a n i m a l sp e rg r o u p .∗P<
.05, ∗∗P<. 01 and ∗∗∗P<. 001, compared with the corresponding
control value. Data were analyzed by the ANOVA or t-test and
complemented by Newman-Keuls post hoc test.
showed that only phenobarbital signiﬁcantly suppressed
STR- and PTZ-induced clonic seizures, with complete
suppression, and was also able to protect against 24-hour
lethality (results not shown).
3.7. IA. Finally, for the VP extract, only the 100 (mg/kg,
p.o.) dose produced inhibitory eﬀects (P<. 05) on memory
retention in the animals treated in the inhibitory avoidance
test (Figure 5).
4. Discussion
The central eﬀects of VP were studied, and the results
for the preliminary neuropharmacological screening showed
Control 50 100 150
∗∗ ∗∗
∗∗
∗∗
LOR
0
600
1200
L
a
t
e
n
c
y
f
o
r
s
l
e
e
p
t
i
m
e
(
s
)
Treatment (mg/kg)
(a)
Control 50 100 150
0
2000
4000
∗∗ ∗∗ ∗∗ ∗∗
T
o
t
a
l
t
i
m
e
o
f
s
l
e
e
p
(
s
)
LOR
Vehicle
Valeriana prionophylla
Lorazepam
Treatment (mg/kg)
(b)
Figure 2: Eﬀect of hydroalcoholic extract of Valeriana prionophylla
(50, 100, and 150mg/kg, p.o.) and lorazepam (2.0mg/kg) on
(a) time latency for sleep and (b) total sleep time induced by
pentobarbital sodium (50mg/kg, i.p.). Date are reported as means
± SEM. N = 8–10 mice ∗∗P<. 01 compared to the control group
(ANOVA followed by Student-Newmann-Keuls analysis).
that this extract exhibited sedative, hypnotic, anxiolytic, and
antidepressant eﬀects.
In this study, the general depressant activity of VP extract
was conﬁrmed by a decrease in the sleeping latency and
an increase in pentobarbital-induced sleeping time, which
may be attributed to an inhibition of the pentobarbital
metabolism or to an action in the regulation of sleep [30].
In addition to the lack of eﬀect of VP extract in the animals
submitted to the rota-rod test, VP also exhibited general
depressantactivity,thoughthisactivitydidnotinterferewith
the animals’ motor system. Myorelaxant eﬀects were not
observed in dosages up to 1000mg/kg in experiments using
diﬀerent extracts of V. oﬃcinalis [31].
The hypnotic action of pentobarbital was demonstrated
by Petty [32] to be mediated by the GABAA receptorEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀects of hydroalcoholic extract of Valeriana prionophylla (50, 100, and 150mg/kg, p.o.) and diazepam (0.75mg/kg, i.p.) in the
elevated plus maze test, in mice. (a) Number of entrances to the open arms, (b) time spent in the open arms; (c) number of entrances to the
closedarms,and(d)timespentintheclosedarms.Eachbarrepresentsthemean ±SEM,from8to10animalspergroup ∗P<. 05, ∗∗P<. 01,
compared with the corresponding control value. Data were analyzed by the ANOVA or t-test and complemented by Newman-Keuls post-hoc
test.
complex. The decrease in rearing and crossing responses
in the open ﬁeld test conﬁrms the depressant activity of
VP, since it is conceded that rearing is a function of the
excitability level of the central nervous system [33]. The
results showed that VP was able to signiﬁcantly decrease
not only the number of crossings, but also the number of
rearings. Since both parameters are indicators of locomotor
activity, horizontal and vertical, respectively, and locomotor
activity is considered as an index of alertness [34] the
decrease these parameters indicates a sedative eﬀect of VP.
In order to study the possible anxiolytic eﬀect of VP
extract, the EPM test was used. Anxiety, a symptom that
accompanies various central nervous system disorders and
is also a disorder in itself, is characterized in humans by a
tense and exhaustive physical alertness [34]. Other animal
species display a variety of defensive reactions in response
to predators, some of which are understood as correlated
states of anxiety [35]. Rodents demonstrate, aversion, fear,
and curiosity when placed in a new environment, and an
overall assessment of behavior can be determined through
theobservationoffreezing,grooming(fear)orrearing,head-
dips (curiosity), and the number of fecal boluses produced
[22, 36].
The EPM has been frequently used to detect and evaluate
the anxiolytic/anxiogenic properties of drugs [37, 38]. The
entries and time spent in the open arms is the main indicator
of fear in the EPM, given the fact that an open area is
extremely aversive to rodents [37, 39]. In addition, in the
open arms there is no thigmotaxis [40] which enhances the
state of fear and aversion in the animals. Our results showed6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀect of hydroalcoholic extract of Valeriana prionophylla
(50,100, and150mg/kg, p.o.) and imipramine(10mg/kg, i.p.) with
acute administration on (a) struggling and (b) immobility time in
mice. Data are reported as means ± SEM. N = 8–10mice. ∗∗P<
.01, ∗∗∗P<. 001 compared to the control group (ANOVA followed
by Student-Newmann-Keuls analysis).
that VP was also able to signiﬁcantly increase the time spent,
as well as the number of entries to the open arms, indicating
a positive response in this test. These results also reinforce
other data obtained in the recent literature, which show
anxiolytic-like eﬀects in more than one species of Valerian
genus [21, 31, 41] making these plants a therapeutic option
in the management of anxiety.
The FST has been validated as a suitable tool for
predicting the anti-depressant properties of drugs [42–
48]. The FST is a behavioral test that in rodents, gives
an indication of the clinical eﬃcacy of various types of
antidepressant drugs. Nowadays, antidepressants are known
to act by several distinct mechanisms at the receptor level,
probably also stimulating similar pathways at the subcellular
level [45]. The administration of VP prior to the test acute
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Figure 5: Eﬀe c to fh y d r o a l c o h o l i ce x t r a c tf r o mValeriana priono-
phylla (50, 100, and 150mg/kg, p.o) and diazepam (0.75mg/kg,
i.p.) given immediately after training in a single trial, on memory
retention of inhibitory avoidance measured 24h later. Each bar
represents the median (interquartile range) for 8 to 10 animals per
group. ∗(P<. 05) comparison between training and test sessions,
#(P<. 05) compared with the corresponding control value in
the session test only. Data were analyzed by the ANOVA test and
complemented by the Kruskal-Wallis or Mann-Whitney U-tests.
reduced total immobility time behavior. Several authors
have proposed that immobility during the test could be an
eﬃcient adaptative response to this stress [25, 43, 44, 47].
VP aﬀects the normal pattern of behavior during the test,
suggesting an antidepressant behavior in response to an
inescapable source of stress.
The eﬀect of VP in memory consolidation was also
examined. In the inhibitory avoidance test in particular,
eﬀects on memory were observed. Our results support the
idea that VP interacts with the GABAA receptor, probably at
the level of the receptor subtypes that mediate BDZ eﬀects,
to produce the sedative and hypnotic activities observed.
Sedative and anxiolytic drugs such as BDZs also have a
propensity to cause cognitive impairment [49].
The lack of eﬀect of VP on PTZ- and STR- induced
convulsions does not exclude the possibility of an anticon-
vulsant eﬀect that could be achieved with higher doses of the
extract or another type of animal model of seizure such as in
the maximal electroshock convulsions or kindling. Recently
Rezvani et al. [50] with doses far higher than those used
in this study demonstrated anticonvulsant eﬀect of aqueous
extract of Valeriana oﬃcinalis in amygdala-kindled rats.
In the search for the active substances of Valeriana oﬃc-
inalis, many compounds have been isolated and identiﬁed
during the last 20 years, but it is still uncertain which of them
is responsible for the observed actions [50]. Concerning the
chemical constituents of VP extract used in our experiments,
classical phytochemical methods were used to determine the
main constituents. The GC technique showed metabolites of
interest, such as isovaleric, 3-methylvaleric, isovalerate allylEvidence-Based Complementary and Alternative Medicine 7
valeric, and 3-methyl-2-oxo valeric acids, glucuronide, and
morphine 3-hydroxybromazepan. Two strands of research
have attempted to indicate the chemical constituents respon-
sible for the central eﬀects of valerian. The ﬁrst proposes that
valerenicacidsareresponsibleforthecentraleﬀectswhilethe
second proposes that the ﬂavonoids are responsible for these
eﬀects.
In animal experiments, valerenic acid or valerian extracts
showed tranquilizing and/or sedative activity [51–57].
Valerenic acid has also been shown to modulate, or at high
concentrations, activate the GABAA receptors, as shown for
recombinant receptors expressed in Xenopus oocytes [54, 55]
or neonatal brain stem neurons [56]. Benke et al. [57]
recently described the existence of a speciﬁc binding site on
GABAA r e c e p t o r sw i t hn Ma ﬃnity for valerenic acid and
valerenol, common constituents of valerian species. Both
agents enhanced the response to GABA in multiple types of
recombinant GABAA receptors. Besides the modulation of
GABAA receptors, several reports have shown the involve-
ment of adenosine receptors in the eﬀects of Valeriana [58–
61].
In relation to ﬂavonoids, several species of valerian
(including V. prionophylla) present these compounds in
their composition. Wasowski et al. [62] through a “ligand-
searching approach” using puriﬁed extracts as far as possible,
were able to report the presence of 6-methylapigenin in
Valeriana wallichii DC and V. oﬃcinalis and to prove that it
is a BDZ binding site (BDZ-bs) ligand, Marder et al. [41]
reported the presence of 2S (−) hesperidin in V. wallichii
and in V. oﬃcinalis and found that it has sedative and sleep-
enhancing properties. 6-methylapigenin, in turn, proved
to have anxiolytic activity and was able to potentiate the
sleep-enhancing properties of hesperidin. Fern´ a n d e ze ta l .
[21] reported the identiﬁcation of the ﬂavone glycoside
linarin in V. oﬃcinalis and the discovery that it has, like
hesperidin, sedative and sleep-enhancing properties that
are potentiated by simultaneous administration of valerenic
acid.6-methylapigenin,anotherﬂavonoidwasalsoidentiﬁed
in extracts of V. oﬃcinalis, and its eﬀects on the central
nervous system were detected [41]. However, the molecular
mechanism of action of any of the valerian ingredients in
vivo is not yet known. In our case, the studies are now in
progress to determine the active principles of V. prionophylla
responsible to the pharmacological eﬀects demonstrated.
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